Overall, Approximately 3 Million Women in The US Are Living with Breast Cancer.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c53882) has announced the addition of "Breast Cancer - Therapeutic and Competitive Insights" to their offering. Introduction Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years). In the past decade the regulatory authorities Noun 1. regulatory authority - a governmental agency that regulates businesses in the public interest regulatory agency administrative body, administrative unit - a unit with administrative responsibilities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. UK estimates, the switching of 100,000 women from tamoxifen tamoxifen (təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancer. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors. to Arimidex will cost nearly 100 million. Research and analysis highlights In the report "Breast Cancer - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of breast cancer therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA and II development, together with general descriptions on drugs and targets. We have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies. Hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been initiated and others generated new results. Protein kinase inhibitors A protein kinase inhibitor is a type of enzyme inhibitor which specifically blocks the action of protein kinase. Kinase inhibitors such as dasatinib are sometimes used in the treatment of cancer. and epothilones have generated a substantial amount of new research data in this field. But, other strategies seem unsuccessful and we are still waiting new information regarding their progress. Scope of this report - Thorough examination of status and impact of several novel drugs in development - Discussion of the challenges in current and future treatment strategies - Anticancer anticancer, n a medicine or substance used to treat cancer. pipeline of most companies in the field Key reasons to read this report - Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast cancer R&D, and the results of clinical trials to date - Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy - One hundred high quality references Some of the drugs included in this analysis: 4HPR (High-Performance Routing) Extensions to IBM's APPN networking that enable SNA data to be sent over frame-based (Ethernet, etc.) and cell-based (ATM) networks. , Anastrozole, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, Erlotinib, Exemestane, Fulvestrant, Gefitinib, Goserelin goserelin /go·se·rel·in/ (go´se-rel?in) a synthetic gonadotropin-releasing hormone; on prolonged administration it suppresses release of gonadotropins and is used as the acetate salt to treat breast and prostate carcinomas and , Imatinib, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Patupilone, Pemetrexed, Temsirolimus, Theratope, Tipifarnib, Trastuzumab, SDX-105. Areas covered: - Cancer Highlights - Current Treatment Strategies - Progress in Current Treatment Strategies - Key Therapeutic Strategies for Future Therapies - Competitive Landscape in Drug Development: The Late Stage Pipeline - Current Drug Development: The Early Stage Pipeline - Drug Index - Company Index 18H Some of the companies included in this analysis: - AstraZeneca - Baxter International Baxter International Inc. (NYSE: BAX), is a global healthcare company with 48,000 employees and 2006 sales of US$10.4 billion. Its headquarters is in Deerfield, Illinois. - Biomira - Bristol Myers-Squibb - Eli Lilly Eli Lilly can refer to:
- Genentech - GlaxoSmithKline - GTx - Isis Pharmaceuticals - Johnson and Johnson - Lorus Therapeutics - Merck - Millennium Pharmaceutical - NeoRx - Novartis Pharmaceuticals - Pfizer - Roche - Salmedix - Schering-Plough - Wyeth - YM BioSciences YM BioSciences is a biotech company towards finding cancer cures. Its recent work includes EGF receptor monoclonal antibody called TheraCIM hR3, which has been given orphan status by the Food and Drug Administration (FDA). It is targeted to treatment of gliomas. For more information visit http://www.researchandmarkets.com/reports/c53882 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion